Published in J Inherit Metab Dis on February 23, 2010
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol (2015) 2.25
The link between the GBA gene and parkinsonism. Lancet Neurol (2012) 1.80
Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med (2011) 1.71
Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol (2013) 1.37
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol (2014) 1.37
Gaucher disease: clinical profile and therapeutic developments. Biologics (2010) 1.27
Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int (2012) 1.23
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis (2010) 1.21
Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov Disord (2012) 1.15
A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol (2011) 1.12
Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain (2014) 1.03
Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease. Proc Natl Acad Sci U S A (2013) 1.01
Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol (2013) 1.00
Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog (2013) 0.93
Greater risk of parkinsonism associated with non-N370S GBA1 mutations. J Inherit Metab Dis (2012) 0.91
The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis (2012) 0.89
The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem (2016) 0.85
The association between ß-glucocerebrosidase mutations and parkinsonism. Curr Neurol Neurosci Rep (2013) 0.85
Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein. PLoS Genet (2015) 0.84
A GCase chaperone improves motor function in a mouse model of synucleinopathy. Neurotherapeutics (2014) 0.82
Neuropathic Gaucher disease. Wien Med Wochenschr (2010) 0.80
A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease. JIMD Rep (2011) 0.78
A sensitive gel-based method combining distinct cyclophellitol-based probes for the identification of acid/base residues in human retaining β-glucosidases. J Biol Chem (2014) 0.78
Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. J Neurol (2013) 0.78
Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PLoS One (2016) 0.78
Bacterial β-Glucosidase Reveals the Structural and Functional Basis of Genetic Defects in Human Glucocerebrosidase 2 (GBA2). ACS Chem Biol (2016) 0.78
Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease. Hum Mol Genet (2016) 0.77
Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration. PLoS Genet (2016) 0.77
The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases. J Biol Chem (2014) 0.77
Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurol Genet (2016) 0.76
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis). Int J Mol Med (2015) 0.76
Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Rep (2014) 0.76
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci (2017) 0.75
Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice. Ann Neurol (2016) 0.75
Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned? Int J Mol Sci (2017) 0.75
Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT. Mol Imaging (2017) 0.75
Parkinson disease in Gaucher disease. J Clin Mov Disord (2017) 0.75
Glucocerebrosidase and parkinsonism: lessons to learn. J Neurol (2016) 0.75
Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson's disease. J Neurosci (2017) 0.75
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med (2004) 7.60
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Parkinson's disease. Lancet (2009) 6.60
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology (2008) 3.83
Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet (2008) 3.06
Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab (2004) 3.06
Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Mov Disord (2005) 2.88
Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med (1998) 2.80
The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol (2009) 2.79
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology (2008) 2.73
Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM (1996) 2.54
Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet (1998) 2.37
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab (2003) 2.29
Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab (2007) 2.21
Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ (2000) 2.17
Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord (2007) 2.12
Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol (2009) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) (1992) 1.96
The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol (2008) 1.87
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology (2006) 1.79
Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab (2001) 1.74
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging (2007) 1.67
A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol (1992) 1.59
Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol (2007) 1.58
Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett (2009) 1.56
Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Mov Disord (2008) 1.48
Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab (2002) 1.47
Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry (2007) 1.47
Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood (2005) 1.41
Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology (2003) 1.36
Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test (1997) 1.35
Burden of parkinsonism: a population-based study. Mov Disord (2003) 1.29
Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. QJM (2000) 1.18
Gaucher disease and parkinsonism. Mol Genet Metab (2005) 1.13
Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis (2005) 1.09
Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet (2006) 1.09
Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement. Skeletal Radiol (1997) 1.07
Gaucher disease and the synucleinopathies. J Biomed Biotechnol (2006) 1.03
Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl (2006) 1.01
55-base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles. Am J Med Genet (1996) 1.01
Parkinson's disease and the heterozygous state for glucocerebrosidase mutations among Brazilians. Parkinsonism Relat Disord (2008) 0.89
Gaucher disease type I complicated with Parkinson's syndrome. Haematologia (Budap) (2002) 0.79
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol (2009) 2.79
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol (2006) 2.47
Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med (2002) 2.44
Therapeutic goals in the treatment of Gaucher disease. Semin Hematol (2004) 2.29
Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics (2008) 2.20
Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol (2007) 2.04
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene (2005) 1.50
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. Blood (2011) 1.45
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med (2009) 1.34
Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord (2010) 1.31
Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr (2004) 1.24
Mutations in GBA2 cause autosomal-recessive cerebellar ataxia with spasticity. Am J Hum Genet (2013) 1.22
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis (2010) 1.21
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics (2006) 1.20
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). Mol Genet Metab (2010) 1.20
Head trauma can initiate the onset of adreno-leukodystrophy. J Neurol Sci (2009) 1.17
Acute confusional migraine may be a presenting feature of CADASIL. Headache (2009) 1.10
Reducing selection bias in case-control studies from rare disease registries. Orphanet J Rare Dis (2011) 1.09
Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy. J Inherit Metab Dis (2010) 1.04
Gaucher disease gene GBA functions in immune regulation. Proc Natl Acad Sci U S A (2012) 1.02
Protease activation during in vivo pancreatitis is dependent on calcineurin activation. Am J Physiol Gastrointest Liver Physiol (2009) 0.99
High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease. J Inherit Metab Dis (2010) 0.97
Pulmonary vascular disease in Gaucher disease: clinical spectrum, determinants of phenotype and long-term outcomes of therapy. J Inherit Metab Dis (2011) 0.96
Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry. J Bone Miner Res (2012) 0.95
Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A (2014) 0.94
Involvement of vps33a in the fusion of uroplakin-degrading multivesicular bodies with lysosomes. Traffic (2009) 0.91
Genome-wide association study of N370S homozygous Gaucher disease reveals the candidacy of CLN8 gene as a genetic modifier contributing to extreme phenotypic variation. Am J Hematol (2012) 0.90
Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma. N Engl J Med (2016) 0.89
Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. Am J Hematol (2010) 0.87
Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene. Ann Neurol (2006) 0.87
Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease. AJR Am J Roentgenol (2008) 0.87
Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. Blood (2012) 0.86
Misdiagnosis of Niemann-Pick disease type C as Gaucher disease. J Inherit Metab Dis (2010) 0.85
Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history. Pediatr Endocrinol Rev (2014) 0.85
Gaucher disease: resetting the clinical and scientific agenda. Am J Hematol (2009) 0.84
Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol (2010) 0.83
Risk factors associated with biliary pancreatitis in children. J Pediatr Gastroenterol Nutr (2012) 0.82
Microvillus inclusion disease associated with coarctation of the aorta and bicuspid aortic valve. J Clin Gastroenterol (2008) 0.82
Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014. Am J Hematol (2014) 0.82
Disease-drug pairs revealed by computational genomic connectivity mapping on GBA1 deficient, Gaucher disease mice. Biochem Biophys Res Commun (2012) 0.81
Prevalence of type 1 Gaucher disease in the United States. Arch Intern Med (2008) 0.81
Parkinson's disease in patients and obligate carriers of Gaucher disease. Parkinsonism Relat Disord (2012) 0.79
Calcium ameliorates diarrhea in immunocompromised children. J Pediatr Gastroenterol Nutr (2013) 0.78
A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders. Drugs R D (2006) 0.77
Primary cerebral Whipple disease presenting as Klüver-Bucy syndrome. Arch Neurol (2009) 0.76
Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis (2011) 0.75
Rare disease clinical research network's urea cycle consortium delivers a successful clinical trial to improve alternate pathway therapy. Hepatology (2013) 0.75
Uncertainty and predictiveness determine attention to cues during human associative learning. Q J Exp Psychol (Hove) (2015) 0.75
Teaching NeuroImages: Molar tooth sign with hypotonia, ataxia, and nystagmus (Joubert syndrome) and hypothyroidism. Neurology (2009) 0.75
The Use of FDG PET Parametric Imaging in the Diagnosis of Olivopontocerebellar Atrophy. Clin Nucl Med (2020) 0.75
Juvenile-onset G(M2)-gangliosidosis in an African-American child with nystagmus. Pediatr Neurol (2008) 0.75
Implicit learning of gaze-contingent events. Psychon Bull Rev (2015) 0.75